Latest news
AstraZeneca Pharma revenue surges 30% in Q1FY27, led by oncology growth - scanx.tradescanx.trade · Mon, 10 Aug 2026 11:28:04 GMTGilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target - TipRanksTipRanks · Fri, 07 Aug 2026 22:51:37 GMTBioNTech: New Leadership and Advancing Oncology Pipeline Underpin Buy Rating Despite Lowered Price Target to $122 - TipRanksTipRanks · Wed, 05 Aug 2026 16:53:58 GMTLeading Companies Fueling Growth and Innovation in the Oncology Clinical Trials Market - openPR.comopenPR.com · Wed, 05 Aug 2026 10:58:18 GMTAstraZeneca stock trades steadily as oncology and vaccines underpin Q1 2026 growth - AD HOC NEWSAD HOC NEWS · Fri, 31 Jul 2026 15:38:47 GMT